Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: Which Patients Benefit from Adjuvant Radiation Therapy and How Much? | Zendy

Lynn Million | Zendy; Sarah S. Donaldson | Zendy

Open Access

Resectable Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: Which Patients Benefit from Adjuvant Radiation Therapy and How Much?

Author(s) -

Lynn Million,

Sarah S. Donaldson

Publication year - 2012

Publication title -

isrn oncology

Language(s) - English

Resource type - Journals

eISSN - 2090-567X

pISSN - 2090-5661

DOI - 10.5402/2012/341408

Subject(s) - medicine , radiation therapy , soft tissue sarcoma , adjuvant radiotherapy , sarcoma , soft tissue , adjuvant therapy , surgical resection , retrospective cohort study , radiology , surgery , chemotherapy , pathology

It remains unclear which children and adolescents with resected nonrhabdomyosarcoma soft tissue sarcoma (NRSTS) benefit from radiation therapy, as well as the optimal dose, volume, and timing of radiotherapy when used with primary surgical resection. This paper reviews the sparse literature from clinical trials and retrospective studies of resected pediatric NRSTS to discern local recurrence rates in relationship to the use of radiation therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research